{'fraction_non_alphanumeric': 0.02524271844660194, 'fraction_numerical': 0.017475728155339806, 'mean_word_length': 5.7894736842105265, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In vitro and non‐invasive in vivo effects of the cannabinoid‐1 receptor agonist AM841 on gastrointestinal motor function in the rat

Cannabinoids have been traditionally used for the treatment of gastrointestinal (GI) symptoms, but the associated central effects, through cannabinoid‐1 receptors (CB1R), constitute an important drawback. Our aims were to characterize the effects of the recently developed highly potent long‐acting megagonist AM841 on GI motor function and to determine its central effects in rats.